Laufer - Miriam K. Laufer Appointed Interim Director of the Center for Vaccine Development and Global Health | University of Maryland School of Medicine

April 30, 2024 | Deborah Kotz

Dr. Laufer is an Established Leader with a Prolific Record in Malaria Research, Pediatric Infectious Diseases, Global Health Initiatives, Research and Educational Programs.

The University of Maryland School of Medicine (UMSOM) Dean, Mark T. Gladwin, MD, announced that Miriam K. Laufer, MD, Professor of Pediatrics, Medicine, and Epidemiology & Public Health, has been appointed as the Interim Head of UMSOM's Center for Vaccine Development and Global Health (CVD).

Dr. Laufer assumes this new leadership role with extensive experience in pediatric infectious diseases and global health and a strong commitment to growth and team building. For the past eight years, she has led the Malaria Research Program at the CVD, establishing one of the largest academic malaria research centers in the country. In this capacity, she served as an Associate Director of the CVD under Kathleen Neuzil, MD, MPH, FIDSA, who has been named the 13th director of the Fogarty International Center (FIC), part of the National Institutes of Health (NIH). Dr. Neuzil will also be the Associate Director for International Research at NIH. Dr. Laufer has been a key figure at the University of Maryland School of Medicine, notably as the Associate Dean for Student Research & Education.

Dr. Laufer has been conducting epidemiological and translational research focusing on global infectious diseases for 20 years with the goal of translating scientific discovery into clinically relevant strategies to improve health. She leads a multi-disciplinary and international team of investigators, trainees, and students in the US and throughout the world, dedicated to developing strategies and tools to support the global effort to tackle infectious diseases. In her laboratory at the University of Maryland, her team uses molecular, genomic, and immunological approaches to address some of the most pressing challenges in controlling the burden of malaria.

"I am thrilled that Dr. Miriam Laufer has been named interim director for CVD," said Dr. Neuzil. "Dr. Laufer is a dynamic leader with extensive experience in global health research and a fierce commitment to education and mentorship. As she takes on this pivotal role, her talent for fostering international collaborations and nurturing the next wave of scientific talent will be instrumental in propelling the CVD to achieve new milestones in vaccine development and global health solutions."

Dr. Laufer, who has been a member of the Department of Pediatrics and the CVD since 2004, is a respected academic leader and seasoned clinician-researcher who has contributed extensively to malaria and global child health research and policy.

"Dr. Laufer has an outstanding track record of success in scientific research and education," said Mark T. Gladwin, MD, Vice President for Medical Affairs, University of Maryland, Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean, University of Maryland School of Medicine. "Her innovative work and leadership in malaria research and her dedication to mentoring young scientists are just two of the many reasons she is ideally suited to lead the Center as we search for a permanent candidate."

Mark T. Gladwin, MD Dr. Laufer's appointment reflects UMSOM's commitment to advancing global health and developing effective interventions against infectious diseases worldwide. Her leadership is expected to continue the Center's tradition of excellence and advance the fight against global health challenges.

As the Interim Head of the Center, Dr. Laufer aims to continue to enhance the Center's impact on global health through basic science and translational and clinical research focusing on vaccine development and novel approaches to combat infectious diseases while fostering global research partnerships.

"It is a privilege to lead this distinguished center that has been my academic home for so long," said Dr. Laufer. “I am committed to supporting our CVD faculty and staff and advancing our mission to address global health disparities and combat infectious diseases.”

About the University of Maryland School of Medicine

Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The combined School of Medicine and Medical System (“University of Maryland Medicine”) has an annual budget of over $6 billion and an economic impact of nearly $20 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2023, the UM School of Medicine is ranked #10 among the 92 public medical schools in the U.S., and in the top 16 percent (#32) of all 192 public and private U.S. medical schools. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu

About the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine

For over 40 years, researchers in the Center for Vaccine Development and Global Health (CVD) have worked domestically and internationally to develop, test, and deploy vaccines to aid the world’s underserved populations. CVD is an academic enterprise engaged in the full range of infectious disease intervention from basic laboratory research through vaccine development, pre-clinical and clinical evaluation, large-scale pre-licensure field studies, and post-licensure assessments. CVD has created and tested vaccines against cholera, typhoid fever, paratyphoid fever, non-typhoidal Salmonella disease, shigellosis (bacillary dysentery), Escherichia coli diarrhea, nosocomial pathogens, tularemia, influenza, coronaviruses, malaria, dengue, ebola and other infectious diseases. CVD’s research covers the broader goal of improving global health by conducting innovative, leading research in Baltimore and around the world. Our researchers are developing new and improved ways to diagnose, prevent, treat, control, and eliminate diseases of global impact, including COVID-19. In addition, CVD’s work focuses on the ever-growing challenge of antimicrobial resistance.

Contact

Deborah Kotz
Senior Director of Media Relations
Office of Public Affairs & Communications
University of Maryland School of Medicine
Email: DKotz@som.umaryland.edu
o: 410-706-4255
c: 410-804-0054
t: @debkotz2

Kathleen M. Neuzil, MD, MPH, Director of the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health, has been named the 13th director of the Fogarty International Center (FIC), which is part of the National Institutes of Health (NIH). Dr. Neuzil will be the first woman to hold the permanent directorship since the center’s founding in 1968 and will also hold the position of Associate Director for International Research at NIH.

Thursday, October 12, 2023

UM School of Medicine's Kirsten Lyke Elected as Member of Prestigious National Academy of Medicine

Kirsten E. Lyke, MD, Professor of Medicine and Physician-Scientist at the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), was elected this week as a new member of the National Academy of Medicine (NAM). She was recognized for her pivotal research in emerging infections and human challenge models that have informed and shaped global vaccine and public health policy.

Thursday, January 26, 2023

Small Study Shows Promise for Antimalarial Monoclonal Antibody to Prevent Malaria

A monoclonal antibody treatment was found to be safe, well tolerated, and effective in protecting against malaria in a small group of healthy volunteers who were exposed to malaria in a challenge study, according to new research published in by researchers at the University of Maryland School of Medicine (UMSOM).

Tuesday, August 09, 2022

New Study Confirms Typhoid Vaccine Safety, Immune Response in Children

A new study, published in The Lancet Global Health, finds typhoid conjugate vaccine, Typbar TCV®, provides immunity for up to 3 years in children as young as 9 months old in Malawi. The research – conducted by the Blantyre Malaria Project, Malawi-Liverpool-Wellcome Trust, and researchers at the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) – found that the TCV vaccine is safe and well tolerated. Importantly, the vaccine can be given to 9-month-old infants at the same time as routine measles-rubella vaccinations without reducing the immune response to either vaccine.

Monday, August 08, 2022

New Study Finds Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against Omicron Subvariant BA.5

A study led in part by investigators at the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health found that although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, those antibody levels decrease substantially within three months. Kirsten E. Lyke, MD, Professor of Medicine at UMSOM and scientist at CVD, is Co-Chair and site Principal Investigator for the study, and Meagan Deming, MD, PhD, Assistant Professor of Medicine at the UMSOM, also a scientist at CVD, is Vice-Chair of the study, which is a collaboration between investigators at the UMSOM’s CVD and the Institute of Human Virology (IHV).

Thursday, March 24, 2022

UM School of Medicine Leads Research to Assess Meningococcal Vaccine for Infants and Young Children in Africa

Researchers at the University of Maryland School of Medicine (UMSOM)’s Center for Vaccine Development & Global Health (CVD) are leading a study to evaluate the use of a pentavalent – or five in one – meningococcal conjugate vaccine (NmCV-5) among infants and young children in the meningitis belt of sub-Saharan Africa. This is the final and pivotal study for World Health Organization (WHO) prequalification of this vaccine, which is the last stage to make the vaccine available for low- and middle-income countries.

Wednesday, January 26, 2022

Trial Co-led by University of Maryland School of Medicine Scientist Confirms Safety of “Mix-and-Match” COVID-19 Vaccine Booster Dosing

A University of Maryland School of Medicine (UMSOM), Center for Vaccine Development and Global Health (CVD), expert is co-leading an ongoing study that was pivotal in recommending adults and teens receive booster COVID-19 shots of their choosing starting in fall 2021. The preliminary clinical trial results, reported today in The New England Journal of Medicine, found that is safe and effective to receive boosters that are the same or a different one from the person’s primary vaccine(s).

Thursday, September 16, 2021

First Efficacy Results from Africa find Typhoid Vaccine to offer 84 Percent Protection against Typhoid Fever

A new study, published in the New England Journal of Medicine, finds a single dose of typhoid conjugate vaccine (TCV) – the only typhoid vaccine licensed for children as young as 6 months – is safe and 84 percent effective in protecting against typhoid in Blantyre, Malawi. These are the first efficacy results from Africa and part of a five-year, multi-country project to accelerate introduction of TCV.

Tuesday, February 25, 2020

World Health Organization Names UMSOM Faculty Member as COVID-19 Advisor

Samba Sow, MD, MSc, FASTMH, Director General of the Center for Vaccine Development in Mali (CVD-Mali), and Adjunct Professor of Medicine at the University of Maryland School of Medicine (UMSOM), was appointed by the World Health Organization (WHO) to serve as a special envoy on issues related to coronavirus COVID-19.

Tuesday, March 20, 2018

UMSOM Vaccine Experts Lead Trial on Avian Flu Vaccine

Vaccine experts at the University of Maryland School of Medicine (UMSOM) have begun multiple clinical trials of vaccines designed to protect against H7N9, an avian influenza virus that was first reported in humans in 2013 in China.

Tuesday, November 21, 2017

UM SOM Scientist Elected as Fellow of American Society of Tropical Medicine and Hygiene

Robert Edelman, MD, a Clinical Professor of Medicine and Pediatrics at the University of Maryland School of Medicine (UM SOM), has been elected as a Fellow by the Board of Directors of the American Society of Tropical Medicine and Hygiene (ASTMH). This honor was awarded for his sustained professional excellence in tropical medicine, hygiene, global health, and related disciplines.

Friday, February 24, 2017

Experimental Malaria Vaccine Provides Durable Protection Against Multiple Strains in NIH Clinical Trial

An experimental malaria vaccine protected healthy subjects from infection with a malaria strain different from that contained in the vaccine, according to a study published this week in the Proceedings of the National Academy of Sciences (PNAS). The research was conducted by scientists at the University of Maryland School of Medicine and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Friday, January 13, 2017

Scientists Identify Vaccination as the Most Cost-Effective Strategy to Sharply Reduce Rabies Deaths in India

Every year in India, 20,000 people are estimated to die from rabies. Most of the victims are children. Nearly all of the deaths occur after victims are bitten by rabid dogs. For years, experts have debated the best strategy to reduce this burden.

Friday, December 23, 2016

Trial Results Confirm Ebola Vaccine Provides High Protection Against Disease

An experimental Ebola vaccine was highly protective against the deadly virus in a major trial in Guinea, according to a new study that included researchers from the University of Maryland School of Medicine (UM SOM).

Monday, January 11, 2016

UM SOM to Collaborate with Industry to Develop a Vaccine to Prevent Common, Deadly Infection

The Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM) will participate in a partnership with industry to develop a vaccine to prevent a group of deadly bacterial infections that occur commonly among hospital patients

Miriam K. Laufer Appointed Interim Director of the Center for Vaccine Development and Global Health